New drug combo shows promise for tough esophageal cancer
NCT ID NCT07403136
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new drug called vebrekotuzumab, which delivers a powerful toxin directly to cancer cells that have a protein called EGFR. It is being tested alone or with an immunotherapy drug in 104 patients whose esophageal cancer has stopped responding to initial treatment. The goal is to see if this approach can shrink tumors and help patients live longer without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vebrekotuzumab (an antibody-drug conjugate targeting EGFR) and a PD-1 inhibitor (immunotherapy)
- What this could lead to
- If successful, this could offer a new second-line treatment option for patients with advanced esophageal cancer, potentially slowing tumor growth and improving survival.
- What could go wrong
- This is an early phase 2 trial with only 104 participants, so results may not apply to all patients. The drug may cause side effects or fail to work better than current therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads